Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (154)	12/6/1998 3:04:00 PM
From: Arthur Radley	Respond to of 1475

Afternoon Rich, It appears that SomatoKine is the main horse that they will be riding in this race. Phase II results look okay to me and I would expect the next milestone to be an alliance with a major to see them through Phase III. As with many biotechs, cash is needed to see them move forward. I caught this one at a good entry level and I'm very pleased with the short-term gains. Would be interested to hear what your friend S. Mori has to say. With LGND, XOMA and now CTRX, I'm holding toooo many biotechs, waiting for the "silver bullet".

To: scaram(o)uche who wrote (154)	12/6/1998 4:44:00 PM
From: Larry Liebman	Read Replies (2) \| Respond to of 1475

Richard, while we're bending your ear, any thoughts as to ARIA. I read their latest investor packet, continued to be impressed. Biotechs overall are reflecting the trend to reward size, capitalization. The "small fry" fry. At some point small-capitalization stocks will see their day. Would you buy more ARIA at $2 ? I'm having trouble deciding where to invest, with a number of smaller biotechs looking highly attractive. P.S. Check out the financial condition of CTRX